<i>In vivo </i>assessment of herb–drug interactions: Possible utility of a pharmacogenetic approach?

Tomlinson, Brian; Hu, Miao; Lee, Vivian

doi:10.1002/mnfr.200700454

Cited by 29 publications

(19 citation statements)

References 141 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…›, increasing; fl, decreasing. (39) flEffect of dolasetron Doxorubicin (39,81) flEffect of doxorubicin Erlotinib (20) flEffect of erlotinib Erythromycin (103) flEffect of erythromycin Estrogens ⁄ progestogens: estradiol, gestodene, levonorgestrel, norethindrone (37,39,50,72) flEffect of contraceptive Etoposide (39,81) flEffect of etoposide Exemestane (20) flEffect of exemestane Fentanyl, Morphine, Oxycodone (21,37,99,111) ›Sedation Fexofenadine (20,44,59,64,65,76,77,79,80,93,97,99,103) flEffect of fexofenadine Finasteride (39) flEffect of finasteride Flutamide (32,39) flEffect of flutamide Gliclazide (103) flEffect of gliclazide Haloperidol (37) flEffect of haloperidol Ifosfamide (39) flEffect of ifosfamide Imatinib (20,59,76,77,79,80,97,99,103) flEffect of imatinib Irinotecan (...…”

Section: Discussionmentioning

confidence: 99%

“…This was done because healthcare professionals, in general, use only textbooks, journal and review articles, as Phenprocoumon (12,18,31,(35)(36)(37)47,65,66,77,80,81,97,103) flEffect of phenprocoumon Phenytoin (32) flEffect of phenytoin Piroxicam, rasagiline, risperidone, tetracycline, tolbutamide, tretinoin (20,37,39,77,102,103) ›Photosensitivity reactions Propofol, sevoflurane (20,99,103) ›Risk of cardiovascular collapse Protease inhibitors: amprenavir, atazanavir, darunavir, fosamprenavir, indinavir, nelfinavir, ritonavir, saquinavir, tipranavir (12,(16)(17)(18)(19)(20)(21)(22)32,34,36,37,47,49,51,64,65,69,72,76,77,(79)(80)…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review

Tsai

Lin

Pickard

et al. 2012

International Journal of Clinical Practice

154

114

View full text Add to dashboard Cite

Summary Background and Aims: The use of herbs and dietary supplements (HDS) alone or concomitantly with medications can potentially increase the risk of adverse events experienced by the patients. This review aims to evaluate the documented HDS‐drug interactions and contraindications. Methods: A structured literature review was conducted on PubMed, EMBASE, Cochrane Library, tertiary literature and Internet. Results: While 85 primary literatures, six books and two web sites were reviewed for a total of 1,491 unique pairs of HDS‐drug interactions, 213 HDS entities and 509 medications were involved. HDS products containing St. John’s Wort, magnesium, calcium, iron, ginkgo had the greatest number of documented interactions with medications. Warfarin, insulin, aspirin, digoxin, and ticlopidine had the greatest number of reported interactions with HDS. Medications affecting the central nervous system or cardiovascular system had more documented interactions with HDS. Of the 882 HDS‐drug interactions being described its mechanism and severity, 42.3% were due to altered pharmacokinetics and 240 were described as major interactions. Of the 152 identified HDS contraindications, the most frequent involved gastrointestinal (16.4%), neurological (14.5%), and renal/genitourinary diseases (12.5%). Flaxseed, echinacea, and yohimbe had the largest number of documented contraindications. Conclusions: Although HDS‐drug interactions and contraindications primarily concerned a relatively small subset of commonly used medications and HDS entities, this review provides the summary to identify patients, HDS products, and medications that are more susceptible to HDS‐drug interactions and contraindications. The findings would facilitate the health‐care professionals to communicate these documented interactions and contraindications to their patients and/or caregivers thereby preventing serious adverse events and improving desired therapeutic outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review

Tsai

Lin

Pickard

et al. 2012

International Journal of Clinical Practice

154

114

View full text Add to dashboard Cite

show abstract

“…Comprehensive review articles specifically highlighting the mechanisms of herb-to-drug interactions, including evidence of herbs that can modulate CYP or P-glycoprotein have recently been published [9,10,11,12]. …”

Section: Mechanisms Of Herb-to-drug Interactions: General Considerationsmentioning

confidence: 99%

“…It is well known that polymorphisms in the genes for drug-metabolizing enzymes or transporters may influence herb-to-drug interactions [12]. For example, ginkgo can induce omeprazole hydroxylation in a CYP2C19 genotype-dependent manner (i.e.…”

Section: Patient Characteristicsmentioning

confidence: 99%

“…Polymorphisms in the genes for CYP enzymes and P-glycoprotein may influence the interactions mediated through these pathways [12]. Probe drugs used in pharmacokinetic trials include midazolam, alprazolam, nifedipine (CYP3A4), chlorzoxazone (CYP2E1), debrisoquine, dextromethorphan (CYP2D6), tolbutamide, diclofenac and flurbiprofen (CYP2C9), caffeine, tizanidine (CYP1A2) and omeprazole (CYP2C19).…”

Section: Mechanisms Of Herb-to-drug Interactions: General Considerationsmentioning

confidence: 99%

See 1 more Smart Citation

Interactions between Herbs and Conventional Drugs: Overview of the Clinical Data

2012

View full text Add to dashboard Cite

This article provides an overview of the clinical evidence of interactions between herbal and conventional medicines. Herbs involved in drug interactions – or that have been evaluated in pharmacokinetic trials – are discussed in this review. While many of the interactions reported are of limited clinical significance and many herbal products (e.g. black cohosh, saw palmetto, echinacea, hawthorn and valerian) seem to expose patients to minor risk under conventional pharmacotherapy, a few herbs, notably St. John’s wort, may provoke adverse events sufficiently serious to endanger the patients’ health. Healthcare professionals should remain vigilant for potential interactions between herbal medicines and prescribed drugs, especially when drugs with a narrow therapeutic index are used.

show abstract

Phytochemical Modulators of Human Drug Metabolism: Drug Interactions with Fruits, Vegetables, and Botanical Dietary Supplements

Gurley¹,

Fifer²,

Gardner³

2012

Encyclopedia of Drug Metabolism and Interactions

View full text Add to dashboard Cite

Plant secondary metabolites (PSMs) have been components of man's diet for millennia and are believed to have played a significant role in steering the functional development of xenobiotic metabolizing enzymes (XMEs) and transporters within the human gastrointestinal tract. Only recently, however, PSMs have been recognized as modulators of human drug disposition. Despite exposure to thousands of structurally diverse dietary phytochemicals, only a few appear to significantly modulate human drug‐metabolizing enzymes and transporters. In some instances, these interactions may have beneficial effects, such as cancer prevention (i.e., isothiocyanates in cruciferous vegetables), whereas others may dramatically affect the pharmacokinetics of concomitantly administered drugs (i.e., furanocoumarins in grapefruit juice). In today's global economy, the opportunity for exposure to more exotic phytochemicals is significantly enhanced. Formulated as concentrated phytochemical extracts, botanical dietary supplements are vehicles for a host of PSMs rarely encountered in the normal diet. When taken with conventional medications, botanical dietary supplements may give rise to clinically significant herb–drug interactions. These interactions stem from phytochemical‐mediated induction and/or inhibition of human drug‐metabolizing enzymes and transporters. In this chapter, the herb–drug interaction risks and mechanisms for several of the most popular dietary supplements are discussed. Botanicals most likely to produce clinically important herb–drug interactions are those whose phytochemicals act as mechanism‐based inhibitors of cytochrome P450 enzyme (CYP) activity (e.g., Hydrastis canadensis, Piper nigrum, and Schisandra chinensis ) or function as ligands for orphan nuclear receptors (e.g., Hypericum perforatum ). In addition, several external factors unrelated to phytochemical pharmacology can augment the drug interaction potential of botanical supplements.

show abstract

In vivo assessment of herb–drug interactions: Possible utility of a pharmacogenetic approach?

Cited by 29 publications

References 141 publications

Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review

Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review

Interactions between Herbs and Conventional Drugs: Overview of the Clinical Data

Phytochemical Modulators of Human Drug Metabolism: Drug Interactions with Fruits, Vegetables, and Botanical Dietary Supplements

Contact Info

Product

Resources

About